S. Kamp, A. M. Fiehn, K. Stenderup, C. Rosada, B. Pakkenberg et al., Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from pat ients with hidradenitis suppurativa, Br J Dermatol, vol.164, issue.5, pp.1017-1039, 2011.

J. J. Kohorst, A. B. Kimball, and M. D. Davis, Systemic associations of hidradenitis suppurativa, J Am Acad Dermatol, vol.73, issue.5, pp.27-35, 2015.

G. H. Jemec and . Suppurativa, N Engl J Med, vol.366, pp.158-64, 2012.

A. Egeberg, G. Jemec, A. B. Kimball, H. Bachelez, G. H. Gislason et al., Prevalence and Risk of Inflammatory Bow el Disease in Patients w ith Hidradenitis Suppurativa, J Invest Dermatol, vol.137, issue.5, pp.1060-1064, 2017.

I. E. Deckers, F. Benhadou, M. J. Koldijk, D. Marmol, V. Horváth et al., Inflammatory bow el disease is associated with hidradenitis suppurativa: Results from a multicenter cross-sectional study, J Am Acad Dermatol, vol.76, issue.1, pp.49-53, 2017.

H. H. Van-der-zee, K. De-winter, C. J. Van-der-woude, and E. P. Prens, The prevalence of hidradenitis suppurativa in 1093 patients w ith inflammatory bow el disease, Br J Dermatol, vol.171, issue.3, pp.673-678, 2014.

G. L. Hold, M. Smith, C. Grange, E. R. Watt, E. M. El-omar et al., Role of the gut microbiota in inflammatory bow el disease pathogenesis: w hat have we learnt in the past 10 years?, World J Gastroenterol, vol.20, issue.5, pp.1192-210, 2014.

H. Guet-revillet, J. P. Jais, M. N. Ungeheuer, H. Coignard-biehler, S. Duchatelet et al., The Microbiological Landscape of Anaerobic Infections in Hidradenitis Suppurativa: A Prospective Metagenomic Study, Clin Infect Dis, vol.65, issue.2, pp.282-291, 2017.

R. J. Lories and I. B. Mcinnes, Primed for inflammation: enthesis-resident T cells, Nat Med, vol.18, issue.7, pp.1018-1027, 2012.

P. Richette, A. Molto, M. Viguier, K. Dawidowicz, G. Hayem et al., Hidradenitis suppurativa associated with spondyloarthritis --results from a multicenter national prospective study, J Rheumatol, vol.41, issue.3, pp.490-494, 2014.

J. M. Von-der-werth and G. B. Jemec, Morbidity in patients w ith hidradenitis suppurativa, Br J Dermatol, vol.144, issue.4, pp.809-822, 2001.

P. Wolkenstein, A. Loundou, K. Barrau, P. Auquier, J. Revuz et al., Quality of lif e impairment in hidradenitis suppurativa: a study of 61 cases, J Am Acad Dermatol, vol.56, issue.4, pp.621-624, 2007.

I. C. Janse, I. E. Deckers, A. D. Van-der-maten, A. Evers, J. Boer et al., Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional study, Br J Dermatol, vol.176, issue.4, pp.1042-1049, 2017.

L. Matusiak and A. Bieniek, Szepietow ski JC. Psychophysical aspects of hidradenitis suppurativa, Acta Derm Venereol, vol.90, issue.3, pp.264-272, 2010.

S. Esmann and G. B. Jemec, Psychosocial impact of hidradenitis suppurativa: a qualitative study, Acta Derm Venereol, vol.91, issue.3, pp.328-360, 2011.

A. J. Onderdijk, H. H. Van-der-zee, S. Esmann, S. Lophaven, D. N. Dufour et al., Depression in patients w ith hidradenitis suppurativa, J Eur Acad Dermatol Venereol, vol.27, issue.4, pp.473-481, 2013.

F. Sampogna, D. Abeni, U. Gieler, L. Tomas-aragones, L. L. Titeca et al., Impairment of Sexual Life in 3,485 Dermatological Outpatients From a Multicentre Study in 13 European Countries, Acta Derm Venereol, vol.97, issue.4, pp.391-397, 2015.

Y. Yang, J. Brazier, L. Orth, and L. , EQ-5D in skin conditions: an assessment of validity and responsiveness, Eur J Health Econ, vol.16, issue.9, pp.927-966, 2015.

M. Sisic, J. S. Kirby, S. Boyal, L. Plant, C. Mclellan et al., Development of a Quality -of-Life Measure for Hidradenitis Suppurativa, J Cutan Med Surg, vol.21, issue.2, pp.152-157, 2017.

C. Mclellan, M. Sisic, H. H. Oon, and J. Tan, Preliminary Validation of the HS-QoL: A Quality-of-Life Measure for Hidradenitis Suppurativa, J Cutan Med Surg, vol.22, issue.2, pp.142-148, 2018.

J. Pinard, R. A. Vleugels, C. Joyce, J. F. Merola, and M. Patel, Hidradenitis suppurativa burden of disease tool: Pilot testing of a diseasespecific quality of life questionnaire, J Am Acad Dermatol, vol.78, issue.1, pp.215-222, 2018.

L. Thorlacius, J. R. Ingram, B. Villumsen, S. Esmann, J. S. Kirby et al., A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process, Br J Dermatol, vol.179, issue.3, pp.642-50, 2018.

A. Y. Finlay and G. K. Khan, Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use, Clin Exp Dermatol, vol.19, issue.3, pp.210-216, 1994.

C. C. Zouboulis, Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic Scoring system to assess HS severity, British Journal of Dermatology, vol.177, pp.1401-1409, 2017.

J. Lapins, W. Ye, O. Nyrén, and L. Emtestam, Incidence of cancer among patients w ith hidradenitis suppurativa. Arch Dermatol, vol.137, pp.730-734, 2001.

J. Shlyankevich, A. J. Chen, G. E. Kim, and A. B. Kimball, Hidradenitis suppurativa is a systemic disease w ith substantial comorbidity burden: a chart-verified case-control analysis, J Am Acad Dermatol, vol.71, issue.6, pp.1144-50, 2014.

C. Lavogiez, E. Delaporte, S. Darras-vercambre, M. De-lassalle, E. Castillo et al., Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa, Dermatology, vol.220, issue.2, pp.147-53, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00486365

E. Shavit, J. Dreiher, T. Freud, S. Halevy, S. Vinker et al., Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa, J Eur Acad Dermatol Venereol, vol.29, issue.2, pp.371-377, 2009.

J. J. Crow-ley, J. R. Mekkes, and C. C. Zouboulis, Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities, Br J Dermatol, vol.171, pp.1561-1565, 2014.

B. G. Vazquez, A. Alikhan, A. L. Weaver, D. A. Wetter, and M. D. Davis, Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota, J Invest Dermatol, vol.133, issue.1, pp.97-103, 2013.

J. J. Kohorst, A. B. Kimball, and M. D. Davis, Systemic associations of hidradenitis suppurativa, J Am Acad Dermatol, vol.73, issue.5, pp.27-35, 2015.

I. M. Miller, C. Ellervik, G. R. Vinding, K. Zarchi, K. S. Ibler et al., Association of metabolic syndrome and hidradenitis suppurativa, JAMA Dermatol, vol.150, issue.12, pp.1273-80, 2014.

T. Tzellos, C. C. Zouboulis, W. Gulliver, A. D. Cohen, P. Wolkenstein et al., Cardiovascular disease risk factors in patients w ith hidradenitis suppurativa: a systematic review and meta-analysis of observational studies, Br J Dermatol, vol.173, issue.5, pp.1142-55, 2015.

J. R. Ingram, S. Jenkins-jones, D. W. Knipe, C. Morgan, R. Cannings-john et al.,

, Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa, Br J Dermatol, vol.178, issue.4, pp.917-924, 2018.

A. Egeberg, G. H. Gislason, and P. R. Hansen, Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa, JAMA Dermatol, vol.152, issue.4, pp.429-463, 2016.

S. Hessam, M. Sand, T. Gambichler, and F. G. Bechara, Correlation of inflammatory serum markers w ith disease severity in patients w ith hidradenitis suppurativa (HS). J Am Acad Dermatol, vol.73, pp.998-1005, 2015.

A. Garg, J. S. Kirby, J. Lavian, G. Lin, and A. Strunk, Sex-and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States, JAMA Dermatol, vol.153, issue.8, pp.760-764, 2017.

A. M. Schrader, I. E. Deckers, H. H. Van-der-zee, J. Boer, and E. P. Prens, Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity, J Am Acad Dermatol, vol.71, issue.3, pp.460-467, 2014.

G. Denny and M. J. Anadkat, The effect of smoking and age on the response to first-line therapy of hidradenitis suppurativa: An institutional retrospective cohort study, J Am Acad Dermatol, vol.76, issue.1, pp.54-59, 2017.

B. G. Vazquez, A. Alikhan, A. L. Weaver, D. A. Wetter, and M. D. Davis, Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota, J Invest Dermatol, vol.133, issue.1, pp.97-103, 2013.

A. Schrader, I. Deckers, H. Van-der-zee, J. Boer, and E. Prens, Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity, J Am Acad Dermatol, vol.71, issue.3, pp.460-467, 2014.

O. J. Clemmensen, Topical treatment of hidradenitis suppurativa w ith clindamycin, Int J Dermatol, vol.22, issue.5, pp.325-333, 1983.

G. B. Jemec and P. Wendelboe, Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa, J Am Acad Dermatol, vol.39, issue.6, pp.971-975, 1998.

V. Bettoli, S. Zauli, A. Borghi, G. Toni, S. Minghetti et al., Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients, J Eur Acad Dermatol Venereol JEADV, vol.28, issue.1, pp.125-131, 2014.

C. Dessinioti, C. Zisimou, V. Tzanetakou, A. Stratigos, and C. Antoniou, Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow -up, Clin Exp Dermatol, vol.41, issue.8, pp.852-859, 2016.

G. Gener, F. Canoui-poitrine, J. E. Revuz, F. O. Poli, F. Gabison et al., Combination therapy w ith clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients, Dermatol Basel Sw itz, vol.219, issue.2, pp.148-54, 2009.

A. B. Kimball, F. Kerdel, D. Adams, U. Mrow-ietz, J. M. Gelfand et al., Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial, Ann Intern Med, vol.157, issue.12, pp.846-55, 2012.

I. Miller, C. D. Lynggaard, S. Lophaven, C. Zachariae, D. N. Dufour et al., A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa, Br J Dermatol, vol.165, issue.2, pp.391-399, 2011.

A. Grant, T. Gonzalez, M. O. Montgomery, V. Cardenas, and F. A. Kerdel, Infliximab therapy for patients w ith moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial, J Am Acad Dermatol, vol.62, issue.2, pp.205-222, 2010.

V. Tzanetakou, T. Kanni, S. Giatrakou, A. Katoulis, E. Papadavid et al., Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial, JAMA Dermatol, vol.152, issue.1, pp.52-61, 2016.

D. R. Adams, J. A. Yankura, A. C. Fogelberg, and A. Be, Treatment of hidradenitis suppurativa w ith etanercept injection. Arch Dermatol, vol.146, pp.501-505, 2010.

A. B. Kimball, M. M. Okun, D. A. Williams, A. B. Gottlieb, K. A. Papp et al., Tw o Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa, N Engl J Med, vol.375, issue.5, pp.422-456, 2016.

. Blok, K. Li, C. Brodmerkel, P. Horvátovich, M. F. Jonkman et al., Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum, Br J Dermatol, vol.174, issue.4, pp.839-885, 2016.

D. C. Van-rappard, M. Leenarts, L. Meijerink-van-'t-oost, and J. R. Mekkes, Comparing treatment outcome of infliximab and adalimumab in patients w ith severe hidradenitis suppurativa, J Dermatol Treat, vol.23, issue.4, pp.284-293, 2012.

, Avis du groupe de travail Le niveau de preuve est insuffisant pour recommander l'emploi de la cryothérapie dans l'HS

H. Yildiz, L. Senol, E. Ercan, and M. E. Bilgili, Karabudak Abuaf O. A prospective randomized controlled trial assessing the efficacy of adjunctive hyperbaric oxygen therapy in the treatment of hidradenitis suppurativa, Int J Dermatol, vol.55, issue.2, pp.232-239, 2016.

A. Brocard, A. Knol, A. Khammari, and B. Dréno, Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatol Basel Sw itz, vol.214, pp.325-332, 2007.

R. Verdolini, N. Clayton, A. Smith, A. Ash, N. Mannello et al., Metformin for the treatment of hidradenitis suppurativa: a little help along the w ay, J Eur Acad Dermatol Venereol JEADV, vol.27, issue.9, pp.1101-1109, 2013.

E. Ducroux, M. A. Ocampo, J. Kanitakis, E. Morelon, D. Jullien et al., Hidradenitis suppurativa after renal transplantation: complete remission after switching from oral cyclosporine to oral tacrolimus, J Am Acad Dermatol, vol.71, issue.5, pp.210-211, 2014.

I. E. Deckers, H. H. Van-der-zee, D. M. Balak, and E. P. Prens, Fumarates, a new treatment option for therapy resistant hidradenitis suppurativa: a prospective open-label pilot study, Br J Dermatol, vol.172, issue.3, pp.828-837, 2015.

M. Feito-rodriguez, E. Sendagorta-cudos, and P. Herranz-pinto, Prepubertal hidradenitis suppurativa successfully treated with botulinum toxin A, Dermatol Surg, vol.35, pp.1300-1302, 2009.

D. J. O'reilly, J. M. Pleat, and A. M. Richards, Treatment of hidradenitis suppurativa with botulinum toxin A, Plast Reconstr Surg, vol.116, pp.1575-1576, 2005.

J. Boer and G. B. Jemec, Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa, Clin Exp Dermatol, vol.35, pp.36-40, 2010.

J. L. Bong, K. Shalders, and E. Saihan, Treatment of persistent painful nodules of hidradenitis suppurativa with cryotherapy, Clin Exp Dermatol, vol.28, issue.3, pp.241-245, 2003.

, de cicatrices rétractiles (notamment, brides axillaires, béance vulvaire, sténose ou incontinence anale) qu'il faut prévenir par des postures et de la kinésithérapie

C. Posch, B. Monshi, T. Quint, I. Vujic, N. Lilgenau et al., The role of w ide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): Retrospective analysis of 74 patients, J Am Acad Dermatol, vol.77, issue.1, pp.123-129, 2017.

J. L. Blok, M. Boersma, J. B. Terra, J. R. Spoo, F. W. Leeman et al., Surgery under general anaesthesia in severe hidradenitis suppurativa: a study of 363 primary operations in 113 patients, J Eur Acad Dermatol Venereol, vol.29, issue.8, pp.1590-1597, 2015.

C. Janse, . Hellinga, and J. L. Blok, Skin-Tissue-sparing Excision w ith Electrosurgical Peeling: A Case Series in Hidradenitis Suppurativa, Acta Derm Venereol, vol.96, pp.390-391, 2016.

K. S. Romanow-ski, A. Fagin, B. Werling, G. Kass, J. Liao et al., Surgical Management of Hidradenitis Suppurativa: A 14-Year Retrospective Review of 98 Consecutive Patients, J Burn Care Res, 2017.

U. Wollina, D. Langner, and B. Heinig, Now ak A: Comorbidities, treatment, and outcome in severe anogenital inverse acne (hidradenitis suppurativa): a 15-year single center report, Int J Dermatol, vol.56, issue.1, pp.109-115, 2016.

J. J. Kohorst, C. L. Baum, C. C. Otley, R. K. Roenigk, J. H. Pemberton et al., Patient Satisfaction and Quality of Life Follow ing Surgery for Hidradenitis Suppurativa, Dermatol Surg, vol.43, issue.1, pp.125-133, 2017.

D. C. Van-rappard, J. E. Mooij, and J. R. Mekkes, 3. van der Zee HH, Prens EP, Boer J Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions, Journal of the American Academy of Dermatology, vol.26, issue.7, pp.475-480, 2010.

Z. Alharbi, J. Kauczok, and N. Pallua, A review of wide surgical excision of hidradenitis suppurativa, BMC Dermatol, vol.12, p.9, 2012.

J. R. Ingram, P. N. Woo, S. L. Chua, A. D. Ormerod, N. Desai et al., Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality, Br J Dermatol, vol.174, issue.5, pp.970-978, 2016.

J. Revuz, clinical evaluation of the severity of hidradenitis suppurativa : Annales de dermatologie et de vénéréologie, vol.142, pp.729-735, 2015.

A. Mehdizadeh, P. G. Hazen, F. G. Bechara, N. Zw-ingerman, M. Moazenzadeh et al., Recurrence of hidradenitis suppurativa after surgical management: A systematic review and meta-analysis, J Am Acad Dermatol, vol.73, issue.5, pp.70-77, 2015.

F. W. Danby, P. G. Hazen, and J. Boer, New and traditional surgical approaches to hidradenitis suppurativa, J Am Acad Dermatol, vol.73, issue.5, pp.62-67, 2015.

C. C. Zouboulis, N. Desai, L. Emtestam, R. E. Hunger, D. Ioannides et al., European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa, J Eur Acad Dermatol Venereol, vol.29, issue.4, p.30, 2015.

L. Z. Ellis, S. Van-hattem, J. R. Spoo, B. Horváth, M. F. Jonkman et al., Surgical treatment of sinuses by deroofing in hidradenitis suppurativa, Dermatol Surg, vol.38, issue.4, pp.494-501, 2011.

I. E. Deckers, Y. Dahi, H. H. Van-der-zee, and E. P. Prens, Hidradenitis suppurativa treated w ith wide excision and second intention healing: a meaningful local cure rate after 253 procedures J Eur Acad Dermatol Venereol, 2017.

, Saint Germain en laye) Chef de projet: Antoine Bertolotti (Dermatologue, CCA) (La Réunion) Dermatologues libéraux: Micheline Moyal-Barraco (Paris), Emilie Sbidian (MCU-PH) (Créteil) Chirurgien plasticien : Pierre Perrot (PUPH) (Nantes) Médecin urgentiste: Youri Yordanov (MCU-PH) (Paris) Médecin généraliste: Stéphanie Sidorkiewicz (CCA) (Paris) Microbiologiste: Olivier Join Lambert (MCU-PH) (Paris) Médecin infectiologue: Eric Caumes

, Une sélection bibliographique des références selon les critères de sélection définis a été effectuée par le chef de projet. Chaque article retenu a été analysé selon les principes de la lecture critique de la littérature, La recherche documentaire a été systématique, hiérarchisée et structurée. Le président (JFS), 2017.

, · Les guidelines ont été analysés selon la grille AGREE

, · Les revues systématiques ont été analysées selon la grille AMSTAR

, Méthode de recherche documentaire Les sources suivantes ont été interrogées : ? pour la littérature internationale : les bases de données Medline

, ? les sites internet publiant des recommandations

, ? les sites Internet des sociétés savantes compétentes dans le domaine étudié

. ?-agence-d, Hidradenitis Suppurativa") OR TI(Hidradenitis NEAR/3 Suppurativa) OR AB(Hidradenitis Suppurativa) OR TI(acne NEAR/3 inversa) OR AB, données Medline MJEMB.EXACT("suppurative hidradenitis") OR MESH.EXACT

, Qua lity of Life") OR MJEMB.EXACT("quality of life index") OR MJEMB.EXACT, AB(verneuil disease*) AND (MESH.EXACT

, AND Correspondait à une étude en cours de realisation (n=1) Correspondaient à des revues non systématiques (n=4) Etaient des redondances avec d'autres articles déjà séléctionnés (n=2)

, Pourrait on la qualifier de « maladie du contact » ou bien de maladie qui rend « intouchable », qui « exclue » ? C'est en effet une pathologie chronique impactant fortement la relation à l'autre, l'image corporelle et qui affecte les organes des sens que, Cette pathologie est invalidante sur plusieurs plans : physique, moral et professionnel

, Selon leurs dires, la douleur est à l'origine de leur irritabilité, de leur colère, de leur agressivité et donc de leur isolement et repli sur soi. Cette douleur invalidante entraine aussi des difficultés au travail, les positions et mouvements de la vie quotidienne sont douloureux et l'évitement du contact physique avec les autres, les proches sera courant en réaction. L'odeur est un élément souvent cité aussi comme contribuant à la mise à distance des autres ayant un impact direct sur la relation : se sentir, avoir l'impression de sentir mauvais? ces odeurs et écoulements provoquent des sentiments de gène, de honte et la crainte du rejet et donc renforcent les comportements d'isolement. Par ailleurs, Sur le plan physique : la douleur, les odeurs et écoulements La douleur est dans la plupart des cas désignée par les patients comme une cause responsable de beaucoup de leurs difficultés

. Dans-le-champ-relationnel, Cet éloignement relationnel s'exprime par une mise à distance émotionnelle des affects, par l'évitement du contact aux autres, par le camouflage des lésions à ses proches, par la gène dans l'établissement d'une relation et par le retrait des investissements dans les liens amicaux ou sociaux, Cette maladie entraine, dans certains cas, une pauvreté de la vie relationnelle, sociale et amicale, une absence ou un renoncement à avoir des relations amoureuses